Previous 10 | Next 10 |
With Republicans in the House of Representatives recently introducing legislation to legalize marijuana at the federal level , the potential for a bipartisan framework is as close as it's ever been. While the patchwork quilt of state-by-state efforts is a workaround of sorts for a growi...
Investing in the cannabis industry for the long haul can be a decision that you thank yourself for later on. The simple reason is that there is significant growth potential there. According to marijuana research company BDSA, the global cannabis market will be worth more than $62 billion by...
Investing In The Cannabis Sector In 2021 Are you looking for the best marijuana stocks to buy next week? Since November 5 th we have seen the top cannabis stocks to invest in begin to rally around Republican-drafted legislation for federal marijuana legalization and reform. The ...
After the market closed on Tuesday, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) released its financial results for the third quarter of 2021 and updated financial guidance for 2021. Total revenues for Jazz increased 39% to $838.1 million versus last year’s third quarter...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are plenty of opportunities as the market heads higher. But despite the positive direction, there are still plenty of stocks to sell. First, let’s take a look at some of the positives. Unemployment numbers ar...
Image source: The Motley Fool. Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) Q3 2021 Earnings Call Nov 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Jazz Pharmaceuticals PLC (JAZZ) Q3 2021 Earnings Call Transcript
Jazz Pharmaceuticals PLC (JAZZ) Q3 2021 Earnings Conference Call November 09, 2021, 16:30 ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Daniel Swisher - President Robert Iannone - EVP, Research & Development & Chief Medical Offi...
Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) are up 1.5% in after-hours trading after the company beat Q3 2021 earnings estimates and raised its 2021 guidance. On a non-GAAP basis, Jazz now expects full-year adjusted net income of $925M-$965M, up from $830M-$910M. Revenue was adjust...
Jazz Pharmaceuticals (NASDAQ:JAZZ): Q3 Non-GAAP EPS of $4.20 beats by $0.89; GAAP EPS of -$0.86 beats by $1.39. Revenue of $838.12M (+39.5% Y/Y) beats by $6.07M. Press Release Net leverage ratio reduced by 0.5x to 4.4x1 in the five months following GW transaction close. Raising full year...
Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences Jefferies London Healthcare Conference 4th Annual Evercore ISI HealthCONx Conference PR Newswire DUBLIN , Nov. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JA...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance PR Newswire – 15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – O...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...